Search - tctmd.com

Displaying 21 - 40 of 64

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for September 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2022

October 03, 2022

Another DOAC Fails in the Setting of Mechanical Heart Valves

News Daily News

Another DOAC Fails in the Setting of Mechanical Heart Valves

September 28, 2022

LAAO vs DOACs: Ongoing Trials and My Prediction

Presentation TCT 2022

LAAO vs DOACs: Ongoing Trials and My Prediction

Presenter: Chad Rammohan

September 18, 2022

TCTMD’s Top 10 Most Popular Stories for August 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2022

September 01, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Stroke, Bleeding Risks Key for Assessing Potential LAAO Benefit

News Daily News

Stroke, Bleeding Risks Key for Assessing Potential LAAO Benefit

August 17, 2022

Warfarin May Speed Progression of Aortic Stenosis and Worsen Outcomes

News Daily News

Warfarin May Speed Progression of Aortic Stenosis and Worsen Outcomes

July 04, 2022

LAA Occlusion With Watchman Provides Good Early Results in China

News Daily News

LAA Occlusion With Watchman Provides Good Early Results in China

June 07, 2022

Risk of Repeat Stroke Underrecognized in Nonstenotic Carotid Lesions

News Daily News

Risk of Repeat Stroke Underrecognized in Nonstenotic Carotid Lesions

May 06, 2022

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

News Daily News

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

May 03, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

TCTMD’s Top 10 Most Popular Stories for October 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

November 02, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.